Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jul 13, 2010

Premium

NimbleGen Systems co-founder Franco Cerrina died this week. He was 62.

Cerrina was found dead in a laboratory of Boston University's College of Engineering's electrical and computer engineering department, of which he was chair. His death has been ruled noncriminal by Boston police, according to news reports.

Prior to joining BU in 2008, Cerrina taught for 24 years at the University of Wisconsin - Madison, where he was the Lynn H. Matthias Professor in Engineering. Cerrina was also director of the university's Center for NanoTechnology, and helped to develop the maskless array synthesizer commercialized by NimbleGen Systems, now Roche NimbleGen. Cerrina was also a co-founder of four other firms: Genetic Assemblies, Codon Devices, Biolitho, and Gen9.

He earned a PhD in solid-state physics from the University of Rome in 1974.


Illumina ast week appointed Gerald Möller to its board of directors.

Möller currently serves as an advisor at HBM Bio Ventures AG, a Swiss investment firm. He is also on several other life sciences and diagnostics boards including Bionostics, Morphosys, and Vivacta.

Moller previously was employed for 23 years at Boehringer Mannheim in Germany, Japan, and the US, including as president of Decentralized Diagnostics, president of Advanced Diagnostics and Biochemicals, CEO of Boehringer Mannheim Therapeutics, and CEO of the worldwide Boehringer Mannheim Group.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.